Notice NOT-NS-21-024 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-AG-21-034 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) will support applications aimed at: (1) determining whether microbial pathogens represent a causal component ?of Alzheimers disease (AD), (2) establishing mechanisms by which microbial pathogens impact neurodegenerative processes in AD, and (3) informing aspects of future translational studies in AD, including the discovery of candidate therapeutics aimed at regulating pathogen-associated networks and molecules in AD.

Notice NOT-CA-21-030 from the NIH Guide for Grants and Contracts

Notice NOT-HD-21-004 from the NIH Guide for Grants and Contracts

Notice NOT-HD-21-001 from the NIH Guide for Grants and Contracts

Experience with analyzing and reporting data using Microsoft Office and statistical and bioinformatics programs such as Prism Graph Pad and Ingenuity Pathway…
From Perfectus Biomed - Fri, 15 Jan 2021 12:41:34 GMT - View all Jackson, WY jobs

Competitive Salary: EMBL: Software developer Location: EMB Cambridge, Cambridgeshire, England

Competitive Salary: EMBL: Helpdesk Bioinformatician - European Genome-phenome Archive Cambridge, Cambridgeshire, England

Funding Opportunity RFA-TR-21-008 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites researchers to submit applications for multi-disciplinary diagnostic strategies for rare diseases that combine machine-assistance, genomic analysis, and clinical consultation. Of particular importance, these strategies must be able to be adopted and performed at the primary or secondary care levels by front-line healthcare providers and be readily integrated into their clinical care workflow.

Funding Opportunity RFA-EY-21-001 from the NIH Guide for Grants and Contracts. A central goal of the BRAIN Initiative is to understand how electrical and chemical signals code information in neural circuits and give rise to sensations, thoughts, emotions and actions. While currently available technologies can provide some understanding, they may not be sufficient to accomplish this goal. For example, non-invasive technologies are low resolution and/or provide indirect measures such as blood flow, which are imprecise; invasive technologies can provide information at the level of single neurons producing the fundamental biophysical signals, but they can only be applied to tens or hundreds of neurons, out of a total number in the human brain estimated at 85 billion. Other BRAIN FOAs seek to develop novel technology (RFA-NS-17-003) or to optimize existing technology ready for in-vivo proof-of-concept testing and collection of preliminary data (RFA-NS-17-004) for recording or manipulating neural activity on a scale that is beyond what is currently possible. This FOA seeks applications for unique and innovative technologies that are in an even earlier stage of development than that sought in other FOAs, including new and untested ideas that are in the initial stages of conceptualization. In addition to experimental approaches, the support provided under this FOA might enable calculations, simulations, computational models, or other mathematical techniques for demonstrating that the signal sources and/or measurement technologies are theoretically capable of meeting the demands of large-scale recording or manipulation of circuit activity in humans or in animal models. The support might also be used for building and testing phantoms, prototypes, in-vitro or other bench-top models in order to validate underlying theoretical assumptions in preparation for future FOAs aimed at testing in animal models.

Funding Opportunity PAR-21-118 from the NIH Guide for Grants and Contracts. The objective of this funding opportunity is to support investigator-initiated, phase I clinical trials for diagnostic and therapeutic interventions for heart, lung, blood, and sleep (HLBS) disorders in adults and children. The proposed trial can be single or multisite. Applicants applying for funding under this FOA should be ready to initiate the clinical trial within the first quarter of the project period. Discussion, submission, and attainment of applicable regulatory (FDA, DSMB, IRB) approvals, and establishment of drug (and placebo, if applicable) supplies, and any necessary third-party agreements should be established by the time of award. If time and support for these and other pre-clinical and/or trial readiness activities are desired, applicants should consider the companion FOA which utilizes an R61/R33 phased approach.

Funding Opportunity PAR-21-119 from the NIH Guide for Grants and Contracts. The objective of this funding opportunity is to support investigator-initiated, Phase I clinical trials for diagnostic and therapeutic interventions for heart, lung, blood, and sleep (HLBS) disorders in adults and children. In addition to supporting clinical trial start-up and implementation activities, this FOA will provide support for final stage preclinical activities needed for the implementation of the proposed trial. All the activities proposed in the R61 phase must be directly related to the therapeutic/diagnostic in preparation for the clinical trial. The proposed trial can be single or multisite. This FOA will utilize a bi-phasic, milestone-driven mechanism of award where the first phase can be used to finalize required pre-trial activities such as stability, shipping studies, and site training.

Funding Opportunity PAR-21-108 from the NIH Guide for Grants and Contracts. The purpose of the NIDCR Dual Degree Dentist Scientist Predoctoral to Postdoctoral Transition Award (F99/K00) is to provide support and mentorship to outstanding students enrolled in integrated dual degree dental (DDS/DMD) and PhD programs over the transition from predoctoral student to postdoctoral scholar. This phased award program will facilitate completion of predoctoral dual degree dentist scientist training (F99) and progression to mentored postdoctoral positions in dental, oral and craniofacial research (K00). It is anticipated that successful completion of this phased award program will enable dentist scientists to progress in their research careers. This Funding Opportunity Announcement (FOA) does not allow prospective fellows to propose to lead an independent clinical trial, but does allow prospective fellows to propose research experience in a clinical trial led by a sponsor or co-sponsor.

Competitive Salary: EMBL: Bioinformatics Community Project Manager Location: Germany (DE)

Notice NOT-ES-21-005 from the NIH Guide for Grants and Contracts

Notice NOT-AI-21-015 from the NIH Guide for Grants and Contracts

Notice NOT-HL-21-001 from the NIH Guide for Grants and Contracts

Funding Opportunity PAR-21-083 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) encourages cooperative agreement applications for implementation of investigator-initiated, high-risk clinical trials and mechanistic studies associated with high-risk clinical trials. Mechanistic work in clinical trials may be of great value because it promotes the understanding of human diseases and the development of future therapeutic modalities. Investigators are encouraged to visit the NIAID website for additional information about the research mission and high-priority research areas of the NIAID (https://www.niaid.nih.gov/research/role). Only one clinical trial may be proposed in each NIAID Clinical Trial Implementation Cooperative Agreement (U01) application.

Funding Opportunity PAR-21-082 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) encourages Small Business Innovation Research (SBIR) grant applications from small business concerns (SBCs) that propose to implement investigator-initiated clinical trials related to the research mission of the NIAID. This program provides support for hypothesis-driven, milestone-driven clinical trials. Although clinical trials not considered high-risk may be proposed, this program encourages high-risk clinical studies. High-risk does not imply human subject or patient risk, but rather defines a study that contains one or more of the following unique features: involves non-routine interventions, administration of an unlicensed product, or administration of a licensed product for an unapproved indication. Mechanistic studies are also encouraged and can be proposed under this program.

Funding Opportunity RFA-HS-21-001 from the NIH Guide for Grants and Contracts. This initiative will fund up to 5 projects to use lessons learned from previous AHRQ primary care practice improvement initiatives to implement and test implementation strategies to address urinary incontinence in women, and to integrate it with specialty care. Projects may draw on community-based resources and/or include multilevel implementation strategies aligning improvement strategies between primary care practices and healthcare systems.